FDA approves drug for postmenopausal osteoporosis
“Postmenopausal osteoporosis is a significant women’s health issue that far too often gets overlooked…,” Dr. David M. Reese, executive vice president of research and development at Amgen, said in a news release Tuesday
Continue Reading »